Traduction de «well as their relatives » (Néerlandais → Français) :

Future projects In 2006, efforts will continue to be made in co-operation with the ICHO and the WVVH towards optimising the care provided to suicide patients and people with suicidal tendencies as well as their relatives.
Projets d’avenir En 2006, en collaboration avec l’ICHO et la WVVH, l’optimalisation des soins aux patients suicidaires, aux suicidants et à leur famille sera poursuivie.

In such parts of the world as Western Europe, the rate of depression, depressiveness, and suicide, which reflect poor levels of well-being, is relatively high, especially in the youngest and the oldest age groups.
Traduction d’un mal-être, la dépression, la dépressivité et le suicide atteignent dans certaines régions comme chez nous, en Europe occidentale, des taux relativement importants, particulièrement dans les tranches d’âge les plus jeunes et les plus âgées.

Interventions aimed at improving people’s sense of coherence with regard to their roles in life, their taking part in and sharing of common values as well as strengthening their ability to deal with change, their credibility and confidence in our society, so as to make it easier for them to adjust to the rapid changes in society.
Interventions qui visent à améliorer le sens de cohérence relativement au rôle que les individus ont à jouer dans la vie, leur participation et le partage de valeurs communes, ainsi que de renforcer leurs capacités de gestion au changement, leur crédibilité et confiance dans nos sociétés afin de faciliter l’adaptation aux changements rapides de nos sociétés.

Indeed, during their phase of psychological maturation, children and teenagers still have very limited mechanisms of self-control well as means to control their impulsiveness at their disposal. As a result, one should constantly be aware of the possibility that they might commit the act.
En effet, en phase de maturation psychologique, les mécanismes de contrôle de soi et de son impulsivité étant encore fort limités chez les enfants et les adolescents, la potentialité du passage à l’acte doit être constamment surveillée.

Training module The following GP organisations have co-operated in view of providing support to general practitioners, as well as improving their competence: the “Vlaams Huisartsen Navormingsinstituut” (VHNI), the “Interuniversitair Centrum voor Huisartsenvorming” (ICHO) and the “Wetenschappelijke Verenining voor Vlaamse Huisartsen” (WVVH) (recently integrated in Domus Medica), as well as the “LOGO” doctors.
Module de formation Dans le cadre du soutien et du développement des compétences des médecins généralistes les organisations de médecins généralistes suivantes ont collaboré: le Vlaams Huisartsen Navormingsinstituut (VHNI), l’Interuniversitair Centrum voor Huisartsenvorming (ICHO) et la Wetenschappelijke Vereniging voor Vlaamse Huisartsen (WVVH), récemment intégrées dans Domus Medica, ainsi qu’avec les médecins « LOGO ».

Most of them said that the training had improved their knowledge as well as their attitudes.
La plupart d’entre eux déclaraient que la formation a amélioré leurs connaissances et leurs attitudes.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

To minimise the risk of MRSA transmission by contacts with the patients and their families during transfer between healthcare facilities, it is recommended to provide clear information to the patients and their relatives about the significance of MRSA carriage and the precautions to be taken to limit its dissemination.
Afin de réduire au minimum le risque de transmission de MRSA par les contacts avec les patients ou leur famille au cours du transfert entre les installations des établissements de soins de santé, il est recommandé d’informer clairement le patient et sa famille de la signification du portage de MRSA et des précautions à prendre pour en limiter la dissémination.

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

since March 2008. This database is an important tool used by the FAMHP departments/services in the context of their activities as well as by the BUM Department itself in order to answer the numerous questions posed by healthcare professionals, patients/consumers, relevant industry or other national or foreign authorities.
since March 2008. This database is an important tool used by the FAMHP departments/services in the context of their activities as well as by the BUM Department itself in order to answer the numerous questions posed by healthcare professionals, patients/consumers, relevant industry or other national or foreign authorities.